| |
| |
| Exchange: |
N/A |
| Security
Type: |
N/A |
| Shares
Out: |
33,020,000 |
| Market
Cap: |
33.35(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$0.6473 - $1.25 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Drug Manufacturers - Major |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Assembly Biosciences is a clinical-stage biotechnology company focused on discovery and development of therapeutics for the treatment of hepatitis B virus (HBV) infection and other viral diseases. Co.'s research and development programs are pursuing various drug candidates with the aim of discovering and developing therapies for patients with HBV. Vebicorvir (VBR) is Co.'s key main inhibitor product candidate that is licensed from Indiana University. Co.'s other main inhibitor product candidates, ABI-H3733, has chemical scaffold that is separate from VBR and 4334. ABI-4334 is Co.'s other main inhibitor product candidate, which chemical scaffold is also separate from VBR and3733.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
1,045,080 |
1,045,080 |
1,045,080 |
| Total Buy Value |
$0 |
$793,364 |
$793,364 |
$793,364 |
| Total People Bought |
0 |
1 |
1 |
1 |
| Total Buy Transactions |
0 |
4 |
4 |
4 |
| Total Shares Sold |
5,087 |
5,564 |
77,441 |
100,632 |
| Total Sell Value |
$65,386 |
$65,715 |
$139,662 |
$183,131 |
| Total People Sold |
4 |
4 |
5 |
6 |
| Total Sell Transactions |
7 |
8 |
19 |
23 |
| End Date |
2024-02-04 |
2023-11-03 |
2023-05-05 |
2022-05-05 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Okazaki Jason A |
CEO and President |
• • – |
2023-06-22 |
4 |
A |
$0.00 |
$0 |
D/D |
50,000 |
176,613 |
|
- |
|
| Delaney William E Iv |
Chief Scientific Officer |
• – – |
2023-05-30 |
4 |
S |
$0.96 |
$4,046 |
D/D |
(4,232) |
112,205 |
|
21% |
|
| Delaney William E Iv |
Chief Scientific Officer |
• – – |
2023-05-23 |
4 |
S |
$1.04 |
$6,825 |
D/D |
(6,561) |
116,437 |
|
21% |
|
| Mchutchison John G |
Director |
– • – |
2023-05-23 |
4 |
S |
$1.04 |
$27,019 |
D/D |
(25,972) |
169,160 |
|
21% |
|
| Okazaki Jason A |
CEO and President |
• • – |
2023-05-23 |
4 |
S |
$1.04 |
$6,825 |
D/D |
(6,561) |
126,613 |
|
21% |
|
| Bjorkquist Jeanette M |
Principal Accounting Officer |
• – – |
2023-05-23 |
4 |
S |
$1.04 |
$285 |
D/D |
(274) |
27,532 |
|
21% |
|
| Delaney William E Iv |
Chief Scientific Officer |
• – – |
2023-05-22 |
4 |
A |
$0.00 |
$0 |
D/D |
35,000 |
122,998 |
|
- |
|
| Mchutchison John G |
Director |
– • – |
2023-05-22 |
4 |
A |
$0.00 |
$0 |
D/D |
117,500 |
295,132 |
|
- |
|
| Okazaki Jason A |
CEO and President |
• • – |
2023-05-22 |
4 |
A |
$0.00 |
$0 |
D/D |
35,000 |
133,174 |
|
- |
|
| Bjorkquist Jeanette M |
Principal Accounting Officer |
• – – |
2023-05-22 |
4 |
A |
$0.00 |
$0 |
D/D |
1,500 |
27,806 |
|
- |
|
| Okazaki Jason A |
CEO and President |
• • – |
2023-03-27 |
4 |
S |
$1.02 |
$4,785 |
D/D |
(4,693) |
102,421 |
|
-12% |
|
| Delaney William E Iv |
Chief Scientific Officer |
• – – |
2023-02-16 |
4 |
A |
$0.00 |
$0 |
D/D |
10,000 |
88,919 |
|
- |
|
| Okazaki Jason A |
CEO and President |
• • – |
2023-02-16 |
4 |
A |
$0.00 |
$0 |
D/D |
12,500 |
107,114 |
|
- |
|
| Bjorkquist Jeanette M |
Principal Accounting OfficerOf |
• – – |
2022-09-09 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
15,830 |
|
-26% |
|
| Mchutchison John G |
Chief Executive Officer |
• • – |
2022-08-08 |
4 |
AS |
$2.13 |
$26,200 |
D/D |
(12,314) |
192,515 |
|
-37% |
|
| Samar Michael P. |
Chief Financial Officer |
• – – |
2022-07-25 |
4 |
AS |
$2.22 |
$4,479 |
D/D |
(2,020) |
77,228 |
|
-42% |
|
| Delaney William E Iv |
Chief Scientific Officer |
• – – |
2022-05-31 |
4 |
AS |
$1.92 |
$8,005 |
D/D |
(4,164) |
76,419 |
|
-14% |
|
| Samar Michael P. |
Chief Financial Officer |
• – – |
2022-03-30 |
4 |
AS |
$2.17 |
$4,953 |
D/D |
(2,285) |
76,748 |
|
4% |
|
| Mchutchison John G |
CEO and President |
• • – |
2022-03-30 |
4 |
AS |
$2.17 |
$10,000 |
D/D |
(4,614) |
204,829 |
|
4% |
|
| Delaney William E Iv |
Chief Scientific Officer |
• – – |
2022-03-30 |
4 |
AS |
$2.17 |
$2,250 |
D/D |
(1,038) |
78,083 |
|
4% |
|
| Okazaki Jason A |
Chief Operating Officer |
• – – |
2022-03-30 |
4 |
AS |
$2.17 |
$2,750 |
D/D |
(1,269) |
94,614 |
|
4% |
|
| Stamm Luisa M |
Chief Medical Officer |
• – – |
2022-03-30 |
4 |
AS |
$2.17 |
$2,250 |
D/D |
(1,038) |
40,315 |
|
4% |
|
| Samar Michael P. |
Chief Financial Officer |
• – – |
2022-03-29 |
4 |
A |
$0.00 |
$0 |
D/D |
26,250 |
79,033 |
|
- |
|
| Mchutchison John G |
CEO and President |
• • – |
2022-03-29 |
4 |
A |
$0.00 |
$0 |
D/D |
83,750 |
209,443 |
|
- |
|
| Delaney William E Iv |
Chief Scientific Officer |
• – – |
2022-03-29 |
4 |
A |
$0.00 |
$0 |
D/D |
25,000 |
79,121 |
|
- |
|
143 Records found
|
|
Page 2 of 6 |
|
|
